Maze Therapeutics, a clinical-stage biopharmaceutical company focused on kidney and metabolic diseases, announced that CEO Jason Coloma will present at the 2026 Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10. These presentations provide Maze an opportunity to update investors on its pipeline, including its Phase 2 programs targeting APOL1-mediated kidney disease and phenylketonuria. Live webcasts will be available on the company website, allowing broader investor access to the latest developments. This engagement highlights Maze's ongoing efforts to advance precision medicines guided by human genetics.
India's military Electro-Optical/Infrared (EO/IR) market is projected to grow to $1.78 billion by 2030 at an 8.9% CAGR, fueled by rising geopolitical tensions and increased border surveillance needs. The market growth is supported by AI integration, ...
Infineon Technologies has partnered with NVIDIA to support the MGX AI Factory ecosystem, focusing on transforming power delivery for advanced AI data centers. Infineon's power management solutions will enable efficient power conversion within NVIDIA'...
Mission Produce has finalized its acquisition of Calavo Growers, creating a stronger, vertically integrated fresh produce company with an expanded footprint in North America. This merger combines two leading avocado providers, enhancing sourcing, pac...
Ferrari's stock has declined about 15% recently, creating a rare entry point with a valuation of 28-31x forward earnings. The company’s cautious approach to electric vehicles, targeting 20% EVs by 2030 alongside hybrids and internal combustion engine...
AirJoule Technologies announced a $15 million registered direct offering of common stock, expected to close around June 1, 2026. The funds will support the commercialization of its AirJoule Core and Prime systems and general corporate purposes. Combi...
